1,904 results on '"Vose, Julie M."'
Search Results
152. Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): One-Year Follow-up of ZUMA-1 Cohort 6 (C6)
153. BET Inhibition As a Targeted Epigenetic Approach to Reverse T Cell Dysfunction in Chronic Lymphocytic Leukemia
154. Long-Term Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium
155. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021
156. Phase 1 trial of carfilzomib in relapsed/refractory peripheral T-cell lymphoma
157. Characteristics and Outcome of Extranodal NK/T-cell Lymphoma in North America: A Retrospective Multi-Institutional Experience
158. Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation
159. Role of radiation therapy in primary mediastinal large B-cell lymphoma in rituximab era: A US population-based analysis
160. 2021 American Society of Hematology: Program Highlights
161. Looking Ahead: What's Next for Hematology/Oncology in 2022?
162. Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: Characteristics, outcomes, and prognostication among a large multicenter cohort
163. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs
164. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management
165. Prognostic Factors for Advanced-Stage Human Immunodeficiency Virus-Associated Classical Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Plus Combined Antiretroviral Therapy: A Multi-Institutional Retrospective Study
166. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project
167. Impact of Pre-transplant Rituximab on Survival after Autologous Hematopoietic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma
168. Unrelated Donor Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma: Long-Term Outcomes
169. Unrelated Donor Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma
170. Genome-Wide miRNA Expression Profiling of Molecular Subgroups of Peripheral T-cell Lymphoma
171. miR-17~92 Promotes Progression of ABC-DLBCL Lymphoma via Regulation of Canonical NF-kB Signaling
172. A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies
173. Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma
174. Optimized adoptive T-cell therapy for the treatment of residual mantle cell lymphoma
175. Appropriate Surveillance for Late Complications in Patients in Remission from Hodgkin Lymphoma
176. Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed/Refractory Follicular Lymphoma: Results from the Phase 1/2 BRUIN Study
177. Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Patients with Prior cBTKi: Safety and Efficacy Including High-Risk Subgroup Analyses from the Phase 1/2 BRUIN Study
178. Mitigating the Risk of Cytokine Release Syndrome (CRS): Preliminary Results from a DLBCL Cohort of Epcore NHL-1
179. Increased Exceptional Response and Overall Survival Advantage for Patients with Multiple Myeloma Receiving Melphalan 200mg/m 2 Vs 140 Mg/m 2 Conditioning for Autologous Hematopoietic Stem Cell Transplantation
180. Integrative Genomic and Transcriptomic Analysis Reveals Targetable Vulnerabilities in Angioimmunoblastic T-Cell Lymphoma
181. Five Year Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium
182. Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study
183. ALK− anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project
184. Influence of Age and Histology on Outcome in Adult Non-Hodgkin Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation (HCT): A Report from The Center For International Blood & Marrow Transplant Research (CIBMTR)
185. Second Autologous Stem Cell Transplantation for Relapsed Lymphoma after a Prior Autologous Transplant
186. Allogeneic Transplants in Follicular Lymphoma: Higher Risk of Disease Progression after Reduced-Intensity Compared to Myeloablative Conditioning
187. Long-Term Outcomes of Autologous Stem Cell Transplantation for Follicular Non-Hodgkin Lymphoma: Effect of Histological Grade and Follicular International Prognostic Index
188. LEADing the Way: Leadership, Empowerment, and Development Conference
189. Addressing Stress and Burnout in Hematology/Oncology Physicians
190. Limited utility of routine surveillance imaging for classical Hodgkin lymphoma patients in first complete remission
191. Lymphoma diagnosis at an academic centre: rate of revision and impact on patient care
192. MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab
193. A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era
194. Outcomes for PTCL: which pathway to success?
195. A novel MYC –non ‐ IG fusion in refractory diffuse large B‐cell lymphoma
196. Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results
197. Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma
198. Minority Enrollment to Clinical Trials: Road to Increased Access
199. Two Step Anti-Thymocyte Globulin (ATG) Is Associated with No Severe Acute Graft Versus Host Disease and Favorable Immune Reconstitution Post Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)
200. Prophylactic Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.